# Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Canonical URL: https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3
Ticker: LCTX
Company: Lineage Cell Therapeutics
Source: Lineage Cell Therapeutics
Published: 2026-07-06 12:00 EST
Original Source URL: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-present-b-riley-securities-2026-mind
## Summary

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M.

## Article Body
CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M.
## Recent Company News
- 2026-07-06 12:00 EST — [Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3) — Source: Lineage Cell Therapeutics
- 2026-06-25 13:46 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-06-25 13:46 EST — [Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-06-25 13:46 EST — [Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech](https://biopharmsignal.com/news/LCTX/lineage-achieves-first-milestone-under-worldwide-collaboration-agreement-with-genentech) — Source: Lineage Cell Therapeutics
- 2026-06-25 13:46 EST — [Lineage Cell Therapeutics Issues Letter to Stockholders](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-issues-letter-to-stockholders) — Source: Lineage Cell Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)